决定了!欧洲药典EP12版将迎来重大更新!
本文转自 上海揽宝 公众号
变化即将来临,欧洲药品质量管理局 (EDQM)近日宣布,欧洲药典许可和出版模式即将迎来重大更新。
即将到来的变化将使欧洲药典的访问和使用变得更容易,更环保,并能更好地满足您多年来的需求和要求。
从第 EP12.1开始,欧洲药典将完全在线提供,所有文本都可在改进的、用户友好的平台上供订阅者使用。会用一种更直观的方法,更现代化的界面,快速高效地访问所需的内容,具有更强的搜索功能、高效的仪表板、新的过滤器和属性等等。
新的年度版本由三卷组成(编号12.1-12.3),对应2025年欧洲药典委员会会议在其中通过的新文本和修订文本,将取代以前三年一个版本,八个增补的更新周期。
此外,将引入365天的许可模式,简化许可管理。欧洲药典将过渡到新的平台和出版模式,以便顺利进行这些更改。
所有第11版的订阅将在过渡期内有效,直至2025年底。
自2026年1月1日起,仅新平台可用。
我公司是欧洲药典委员会(EDQM)签约分销商(以旗下公司名义),具体资质可联系我公司查看。
我司将及时推送关于欧洲药典的最新消息,也欢迎广大客户联系我们订阅购买。
注意:基于税务要求,有关进口产品的销售我司可能会用旗下公司抬头与您签订合同、结算和开票,以方便报税记账,请知悉。
欧洲药品质量管理局通知原文
Change is in the air, and the European Directorate for the Quality of Medicines & HealthCare (EDQM) would like to give you, as an important stakeholder, advance notice of the improvements coming to the European Pharmacopoeia licencing and publication models. The upcoming changes will make it easier to access and use, more environmentally friendly and better able to meet your requirements and needs for many years to come.
Starting with Issue 12.1, the European Pharmacopoeia will be available exclusively online, with all texts available to subscribers on an improved, user-friendly platform. You will discover a more visual approach with a modern, intuitive interface for quick and efficient access to the content you need, featuring enhanced search capabilities, a time-saving dashboard, new filters and attributes, and much more.
An annual edition consisting of three issues (numbered 12.1 to 12.3), corresponding to the European Pharmacopoeia Commission sessions in 2025 at which new and revised texts are adopted, will replace the former three-year cycle comprising one edition and eight supplements. Likewise, a 365-day licencing model will be introduced, with simplified licence management.
The European Pharmacopoeia will transition to the new platform and publication models to ease in the changes. All subscriptions to the 11th Edition will remain valid during the transitional period until the end of 2025. As of 1 January 2026, only the new platform will be available.